JP2024517935A5 - - Google Patents
Info
- Publication number
- JP2024517935A5 JP2024517935A5 JP2023569873A JP2023569873A JP2024517935A5 JP 2024517935 A5 JP2024517935 A5 JP 2024517935A5 JP 2023569873 A JP2023569873 A JP 2023569873A JP 2023569873 A JP2023569873 A JP 2023569873A JP 2024517935 A5 JP2024517935 A5 JP 2024517935A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- combination
- cyp3a inhibitor
- ritonavir
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201743P | 2021-05-11 | 2021-05-11 | |
| US63/201,743 | 2021-05-11 | ||
| PCT/US2022/028434 WO2022240788A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517935A JP2024517935A (ja) | 2024-04-23 |
| JP2024517935A5 true JP2024517935A5 (enExample) | 2025-05-16 |
Family
ID=84028802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569873A Pending JP2024517935A (ja) | 2021-05-11 | 2022-05-10 | Ｃｙｐ３ａ阻害剤及びアザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220370481A1 (enExample) |
| EP (1) | EP4337208A4 (enExample) |
| JP (1) | JP2024517935A (enExample) |
| KR (1) | KR20240006660A (enExample) |
| CN (1) | CN117651556A (enExample) |
| AU (1) | AU2022273615A1 (enExample) |
| BR (1) | BR112023023638A2 (enExample) |
| CA (1) | CA3219761A1 (enExample) |
| IL (1) | IL308318A (enExample) |
| MX (1) | MX2023013361A (enExample) |
| WO (1) | WO2022240788A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20240350524A1 (en) * | 2023-04-06 | 2024-10-24 | Abbvie Inc. | Dosing regimens for use in preventing relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation with venetoclax in combination with azacitidine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3258941A4 (en) * | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| CN109789143A (zh) * | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| WO2020257671A1 (en) * | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
-
2022
- 2022-05-10 WO PCT/US2022/028434 patent/WO2022240788A1/en not_active Ceased
- 2022-05-10 CN CN202280049025.3A patent/CN117651556A/zh not_active Withdrawn
- 2022-05-10 IL IL308318A patent/IL308318A/en unknown
- 2022-05-10 AU AU2022273615A patent/AU2022273615A1/en not_active Abandoned
- 2022-05-10 BR BR112023023638A patent/BR112023023638A2/pt unknown
- 2022-05-10 EP EP22808147.7A patent/EP4337208A4/en not_active Withdrawn
- 2022-05-10 CA CA3219761A patent/CA3219761A1/en active Pending
- 2022-05-10 MX MX2023013361A patent/MX2023013361A/es unknown
- 2022-05-10 KR KR1020237042683A patent/KR20240006660A/ko active Pending
- 2022-05-10 JP JP2023569873A patent/JP2024517935A/ja active Pending
- 2022-05-10 US US17/741,356 patent/US20220370481A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hartmann et al. | Treatment of cats with feline infectious peritonitis | |
| JP2023522166A5 (enExample) | ||
| KR101390144B1 (ko) | 염증성 장질환 치료제 | |
| CN109985237B (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| JP2006511538A5 (enExample) | ||
| CN116685353A (zh) | 血管性水肿的预防和治疗 | |
| CN117651556A (zh) | 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案 | |
| KR102512494B1 (ko) | 의약 | |
| Ross et al. | Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis | |
| JP2024525164A5 (enExample) | ||
| JP2023530001A (ja) | ウイルス感染症の処置のための化合物 | |
| CN111686108A (zh) | 表小檗碱在制备抗幽门螺旋杆菌感染药物中的应用 | |
| RU2023129203A (ru) | Применения в лечении миелодиспластических синдромов в комбинации с ингибитором cyp3a и азацитидином | |
| CN110891574B (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| JP2024517318A5 (enExample) | ||
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| JP7653712B2 (ja) | 高リスク骨髄異形成症候群の治療薬 | |
| JP2026507878A5 (enExample) | ||
| TWI674094B (zh) | 治療或緩解慢性骨髓性白血病用之醫藥組合物 | |
| CN104095853A (zh) | 洛匹那韦在制备预防或治疗缺血性心脑血管疾病的药物中的应用 | |
| Hameed et al. | Recent Developments in Therapies and Strategies Against COVID-19 | |
| RU2498797C2 (ru) | Комбинированное средство для лечения гриппа и орви | |
| CN102149389A (zh) | 生物素化艾屈肝素用于降低抗血栓治疗期间出血发生率的用途 | |
| CN104083366A (zh) | 硫酸阿扎那韦在制备预防或治疗缺血性心脑血管疾病的药物中的应用 | |
| CN104083370A (zh) | 硫酸茚地那韦在制备预防或治疗缺血性心脑血管疾病的药物中的应用 |